Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials

Abstract Background Itch, skin pain, and sleep disturbance are burdensome symptoms in atopic dermatitis (AD) that negatively influence a patient’s quality of life (QoL). Objective To evaluate the impact of baricitinib on patient-reported outcomes (PROs) in adult patients with moderate-to-severe AD, and explore the association between improvement in key signs and symptoms of AD with improvements in QoL and patient’s assessment of disease severity. Methods Data were analyzed from two phase III monotherapy trials (BREEZE-AD1/BREEZE-AD2) in which patients were randomized 2:1:1:1 to once-daily placebo, baricitinib 1-mg, 2-mg, or 4-mg for 16 weeks and assessed using PRO measures. Results At week 16, baricitinib 4-mg and 2-mg significantly reduced itch severity (Itch Numeric Rating Scale (NRS) (BREEZE-AD1: percent change from baseline −36.6% and −29.4% vs. placebo (–12.0%), p≤.001 and p≤.05; BREEZE-AD2: −47.2% and −46.9% vs. placebo (–16.6%), p≤.001). Baricitinib significantly reduced SCORing AD (SCORAD) pruritus (4-mg in BREEZE-AD1 and 2-mg in BREEZE-AD2) and Patient Oriented Eczema Measure (POEM) itch (both doses). Improvements in skin pain severity and sleep disturbance were also observed. Improvements in AD symptoms showed higher correlations with patients’ assessment of AD severity and QoL than improvements in skin inflammation. Conclusions Baricitinib significantly improved symptoms in patients with moderate-to-severe AD. ClinicalTrials.gov identifiers NCT03334396 (BREEZE-AD1) and NCT03334422 (BREEZE-AD2).

[1]  A. Egeberg,et al.  Pain severity and use of analgesic medication in adults with atopic dermatitis: a cross‐sectional study , 2020, The British journal of dermatology.

[2]  J. Silverberg,et al.  Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials , 2020, The British journal of dermatology.

[3]  C. Flohr,et al.  The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group , 2019, The British journal of dermatology.

[4]  L. Eicher,et al.  A systematic review of factors influencing treatment adherence in chronic inflammatory skin disease – strategies for optimizing treatment outcome , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

[5]  D. Margolis,et al.  Pain is a common and burdensome symptom of atopic dermatitis in United States adults. , 2019, The journal of allergy and clinical immunology. In practice.

[6]  J. Silverberg,et al.  Exploring content and psychometric validity of newly developed assessment tools for itch and skin pain in atopic dermatitis , 2019, Journal of Patient-Reported Outcomes.

[7]  D. Margolis,et al.  Atopic Dermatitis in US Adults: From Population to Health Care Utilization. , 2019, The journal of allergy and clinical immunology. In practice.

[8]  E. Simpson,et al.  The socioeconomics of atopic dermatitis. , 2019, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[9]  M. Blaiss,et al.  The burden of atopic dermatitis. , 2018, Allergy and asthma proceedings.

[10]  L. Skov,et al.  Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: A systematic review and meta‐analysis , 2018, Journal of the American Academy of Dermatology.

[11]  L. Kircik,et al.  Rapid Onset of Action in Patients With Moderate-to-Severe Plaque Psoriasis With Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination. , 2018, Journal of drugs in dermatology : JDD.

[12]  D. Margolis,et al.  Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study. , 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[13]  A. Muraro,et al.  Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[14]  H. S. Kim,et al.  Reliability and validity of the Atopic Dermatitis Symptom Score (ADSS) , 2018, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[15]  A. Linneberg,et al.  Atopic dermatitis is associated with anxiety, depression, and suicidal ideation, but not with psychiatric hospitalization or suicide , 2018, Allergy.

[16]  J. Silverberg,et al.  Burden of skin pain in atopic dermatitis. , 2017, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[17]  J. Chao,et al.  Burden of Atopic Dermatitis in the United States: Analysis of Healthcare Claims Data in the Commercial, Medicare, and Medi-Cal Databases , 2017, Advances in Therapy.

[18]  W. Liao,et al.  Frequency and Management of Sleep Disturbance in Adults with Atopic Dermatitis: A Systematic Review , 2017, Dermatology and Therapy.

[19]  J. Piercy,et al.  Discordance Between Physician- and Patient-Reported Disease Severity in Adults with Atopic Dermatitis: A US Cross-Sectional Survey , 2017, American Journal of Clinical Dermatology.

[20]  A. Gottlieb,et al.  From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis , 2017, Journal of the American Academy of Dermatology.

[21]  J. Ring,et al.  ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

[22]  T. Bieber,et al.  Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults. , 2016, Journal of the American Academy of Dermatology.

[23]  J. Silverberg,et al.  Association between Atopic Dermatitis and Depression in US Adults. , 2015, The Journal of investigative dermatology.

[24]  A. Finlay,et al.  Determining the Minimal Clinically Important Difference and Responsiveness of the Dermatology Life Quality Index (DLQI): Further Data , 2015, Dermatology.

[25]  S. Takeuchi,et al.  Poor adherence to oral and topical medication in 3096 dermatological patients as assessed by the Morisky Medication Adherence Scale-8 , 2014, The British journal of dermatology.

[26]  Masutaka Furue,et al.  The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. , 2014, The Journal of allergy and clinical immunology.

[27]  R. Hay,et al.  The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. , 2014, The Journal of investigative dermatology.

[28]  S. Feldman,et al.  Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. , 2014, Journal of the American Academy of Dermatology.

[29]  J. Silverberg,et al.  Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization , 2013, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[30]  J. Szepietowski,et al.  Relationship between itch and psychological status of patients with atopic dermatitis , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[31]  T Reunala,et al.  Patient‐Oriented SCORAD (PO‐SCORAD): a new self‐assessment scale in atopic dermatitis validated in Europe , 2011, Allergy.

[32]  G. Bonsel,et al.  Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) , 2011, Quality of Life Research.

[33]  S. Feldman,et al.  Factors affecting sleep quality in patients with psoriasis. , 2010, Journal of the American Academy of Dermatology.

[34]  H. Williams,et al.  The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. , 2004, Archives of dermatology.

[35]  R. Snaith,et al.  The Hospital Anxiety And Depression Scale , 2003, Health and quality of life outcomes.

[36]  A. Finlay,et al.  Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use , 1994, Clinical and experimental dermatology.

[37]  A. Zbrozek,et al.  The Validity and Reproducibility of a Work Productivity and Activity Impairment Instrument , 1993, PharmacoEconomics.

[38]  Huston Gj,et al.  The Hospital Anxiety and Depression Scale. , 1987, The Journal of rheumatology.

[39]  J. Krueger,et al.  Atopic dermatitis endotypes and implications for targeted therapeutics. , 2019, The Journal of allergy and clinical immunology.

[40]  J. Gelfand,et al.  The burden of atopic dermatitis in US adults: Health care resource utilization data from the 2013 National Health and Wellness Survey , 2018, Journal of the American Academy of Dermatology.

[41]  J. Hanifin,et al.  New and developing therapies for atopic dermatitis* , 2018, Anais brasileiros de dermatologia.

[42]  A. Adamson The Economics Burden of Atopic Dermatitis. , 2017, Advances in experimental medicine and biology.

[43]  A. Torrelo,et al.  Atopic dermatitis: impact on quality of life and patients' attitudes toward its management. , 2012, European journal of dermatology : EJD.

[44]  V. Beltrani,et al.  Atopic dermatitis in adults. , 2012, Dermatitis : contact, atopic, occupational, drug.

[45]  T. Bieber Atopic dermatitis. , 2010, Annals of dermatology.

[46]  J. Ring,et al.  Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. , 1997, Dermatology.

[47]  Julia Brasch,et al.  Severity Scoring of Atopic Dermatitis: The SCORAD Index , 1993 .

[48]  A. Taïeb,et al.  Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. , 1993, Dermatology.